89Zr标记高密度脂蛋白纳米颗粒PET显像揭示食管癌患者的肿瘤摄取
本研究为首个89Zr-HDL人体肿瘤学研究,纳入9例T2期及以上食管癌患者,在放化疗前进行系列89Zr-HDL PET/CT显像。结果显示静脉注射的HDL纳米颗粒在肿瘤中随时间累积,给药安全,肿瘤摄取与葡萄糖代谢、细胞密度、灌注及血管通透性均不相关,提示存在特异性机制。
要点
- 9例食管癌患者注射89Zr-HDL后,肿瘤SUVpeak在1、24、72小时分别为3.5±1.1、5.5±2.1、5.7±1.4,随时间增加。
- 89Zr-HDL的有效剂量为0.523±0.040 mSv/MBq,给药后未观察到不良事件。
- 肿瘤摄取与18F-FDG PET/CT及3-T MRI测得的代谢、细胞密度、灌注和血管通透性均不相关。
核心结论
- 据作者所知,这是首个在人类肿瘤学中开展的89Zr-HDL研究;89Zr-HDL PET/CT显像显示静脉给予的HDL纳米颗粒在食管癌患者肿瘤中累积,且给药安全。
- 这些发现可能支持将HDL纳米颗粒开发为药物递送的临床平台;89Zr-HDL显像可能指导药物开发并作为个体化治疗的生物标志物。
研究设计与样本
- 研究纳入原发食管癌且分期为T2及以上的患者,在开始放化疗前进行系列89Zr-HDL PET/CT显像。
- 患者另接受常规18F-FDG PET/CT和3-T MRI扫描(扩散加权成像/体素内不相干运动成像及动态增强MRI),以评估肿瘤葡萄糖代谢、肿瘤细胞密度与微循环灌注、肿瘤血管通透性。
- 对肿瘤活检组织采用免疫荧光染色分析HDL清道夫受体B1和巨噬细胞标志物CD68的表达。
- 共9例腺癌或鳞状细胞癌患者完成了全部研究程序。
主要发现
- 注射89Zr-HDL(39.2±1.2 MBq,均值±标准差)后,血池SUVmean随时间下降:1、24、72小时分别为11.0±1.7、6.5±0.6、3.3±0.5。
- 肝脏SUVmean相对恒定:1、24、72小时分别为4.1±0.6、4.0±0.8、4.3±0.8;脾脏SUVmean分别为4.1±0.3、3.4±0.3、3.1±0.4;肾脏SUVmean随时间明显升高:1、24、72小时分别为4.1±0.9、9.3±1.4、9.6±2.0。
- 肿瘤摄取(SUVpeak)随时间增加:1小时为3.5±1.1,24小时为5.5±2.1(P=0.016),72小时为5.7±1.4(P=0.001)。
- 89Zr-HDL的有效剂量为0.523±0.040 mSv/MBq;给予89Zr-HDL后未观察到不良事件。
- PET/CT和3-T MRI测量的肿瘤葡萄糖代谢、肿瘤细胞密度与微循环灌注、肿瘤血管通透性与89Zr-HDL肿瘤摄取均不相关,提示存在特异性机制介导89Zr-HDL的累积。
关键数值与推荐
- 患者入组条件为原发食管癌、分期T2及以上。
- 89Zr-HDL注射活度为39.2±1.2 MBq(均值±标准差)。
- 肿瘤SUVpeak在1小时与24小时比较P=0.016,在1小时与72小时比较P=0.001。
- 89Zr-HDL有效剂量为0.523±0.040 mSv/MBq。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nanomedicine holds promise for the delivery of therapeutic and imaging agents to improve cancer treatment outcomes. Preclinical studies have demonstrated that high-density lipoprotein (HDL) nanoparticles accumulate in tumor tissue on intravenous administration. Whether this HDL-based nanomedicine concept is feasible in patients is unexplored. Using a multimodal imaging approach, we aimed to assess tumor uptake of exogenously administered HDL nanoparticles in patients with esophageal cancer. Methods: The HDL mimetic CER-001 was radiolabeled using 89Zr to allow for PET/CT imaging. Patients with primary esophageal cancer staged T2 and above were recruited for serial 89Zr-HDL PET/CT imaging before starting chemoradiation therapy. In addition, patients underwent routine 18F-FDG PET/CT and 3-T MRI scanning (diffusion-weighted imaging/intravoxel incoherent motion imaging and dynamic contrast-enhanced MRI) to assess tumor glucose metabolism, tumor cellularity and microcirculation perfusion, and tumor vascular permeability. Tumor biopsies were analyzed for the expression of HDL scavenger receptor class B1 and macrophage marker CD68 using immunofluorescence staining. Results: Nine patients with adenocarcinoma or squamous cell carcinoma underwent all study procedures. After injection of 89Zr-HDL (39.2 ± 1.2 [mean ± SD] MBq), blood-pool SUVmean decreased over time (11.0 ± 1.7, 6.5 ± 0.6, and 3.3 ± 0.5 at 1, 24, and 72 h, respectively), whereas liver and spleen SUVmean remained relatively constant (4.1 ± 0.6, 4.0 ± 0.8, and 4.3 ± 0.8 at 1, 24, and 72 h, respectively, for the liver; 4.1 ± 0.3, 3.4 ± 0.3, and 3.1 ± 0.4 at 1, 24, and 72 h, respectively, for the spleen) and kidney SUVmean markedly increased over time (4.1 ± 0.9, 9.3 ± 1.4, and 9.6 ± 2.0 at 1, 24, and 72 h, respectively). Tumor uptake (SUVpeak) increased over time (3.5 ± 1.1 and 5.5 ± 2.1 at 1 and 24 h, respectively [P = 0.016]; 5.7 ± 1.4 at 72 h [P = 0.001]). The effective dose of 89Zr-HDL was 0.523 ± 0.040 mSv/MBq. No adverse events were observed after the administration of 89Zr-HDL. PET/CT and 3-T MRI measures of tumor glucose metabolism, tumor cellularity and microcirculation perfusion, and tumor vascular permeability did not correlate with tumor uptake of 89Zr-HDL, suggesting that a specific mechanism mediated the accumulation of 89Zr-HDL. Immunofluorescence staining of clinical biopsies demonstrated scavenger receptor class B1 and CD68 positivity in tumor tissue, establishing a potential cellular mechanism of action. Conclusion: To our knowledge, this was the first 89Zr-HDL study in human oncology. 89Zr-HDL PET/CT imaging demonstrated that intravenously administered HDL nanoparticles accumulated in tumors of patients with esophageal cancer. The administration of 89Zr-HDL was safe. These findings may support the development of HDL nanoparticles as a clinical delivery platform for drug agents. 89Zr-HDL imaging may guide drug development and serve as a biomarker for individualized therapy.
引用
- Zheng KH, Kroon J, Schoormans J, et al. 89Zr-Labeled High-Density Lipoprotein Nanoparticle PET Imaging Reveals Tumor Uptake in Patients with Esophageal Cancer. J Nucl Med. 2022. PMID: 35738904. doi:10.2967/jnumed.121.263330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。